Price$2.34+0.00 (+0.00%)
01:30 PM03:00 PM
News · 26 weeks17-87%
2026-03-012026-08-23
Mix1190d
- Insider8(73%)
- Market1(9%)
- SEC Filings1(9%)
- Other1(9%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aytu BioPharma Inc.SCHEDULE 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
- INSIDERChief Commercial Officer Pyszczymuka Greg was granted 20,000 shares, increasing direct ownership by 55% to 56,102 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERChief Executive Officer Disbrow Joshua R. was granted 30,000 shares, increasing direct ownership by 14% to 237,203 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERChief Business Officer Disbrow Jarrett was granted 15,000 shares, increasing direct ownership by 24% to 76,568 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERChief Financial Officer Selhorn Ryan J was granted 25,000 shares, increasing direct ownership by 50% to 74,743 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERDirector Liu Vivian H was granted 10,000 shares, increasing direct ownership by 50% to 29,825 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERDirector Jain Abhinav was granted 10,000 shares, increasing direct ownership by 51% to 29,500 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERDirector Dockery Carl was granted 10,000 shares, increasing direct ownership by 47% to 31,152 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERDirector Donofrio John Jr. was granted 10,000 shares, increasing direct ownership by 73% to 23,762 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- SECAytu BioPharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- NEWSAytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it will be participating in a Fireside Q&A hosted by Lake Street Capital Markets at the Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClub on Wednesday, June 17, 2026, at 10:30 a.m. Pacific time at the Bellagio Resort & Hotel.To access the live webcast, please use the following information:Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClubDate: Wednesday, June 17,
- NEWSAytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.Company WebcastThe webcast presentation will take place at 9:15 a.m. Eastern time on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2026/ or directly at https://app.w
- SECSEC Form 10-Q filed by Aytu BioPharma Inc.10-Q - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECAytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- NEWSAytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial ResultsEXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth ratesTotal net revenue of $12.4 millionAdjusted EBITDA1 of $(2.8) million, which includes EXXUA™ (gepirone) extended-release tablets ("EXXUA") launch investments as the Company enters the over $22 billion United States prescription major depressive disorder ("MDD") market$26.7 million cash balance at March 31, 2026Company to host conference call and webcast today, May 13, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / May 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company
- NEWSAytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its third quarter of fiscal 2026, after the market close on Wednesday, May 13, 2026. The Company has scheduled a conference call and webcast that same day, Wednesday, May 13, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Wednesday, May 13, 2026, at 4:30 p.m. Eastern time.Call-in Information: I
- SECAytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aytu BioPharma Inc.SCHEDULE 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
- SECSEC Form 10-Q filed by Aytu BioPharma Inc.10-Q - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECAytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- NEWSAytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial ResultsTotal net revenue of $15.2 millionAdjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") marketCompany to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern timeDENVER, CO / ACCESS Newswire / February 3, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system dis
- NEWSAytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its second quarter of fiscal 2026, after the market close on Tuesday, February 3, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, February 3, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Tuesday, February 3, 2026, at 4:30 p.m. Eastern time.Call-in In
- SECAytu BioPharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- NEWSAytu BioPharma Recaps Investor Day Held on January 20, 2026DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today provided a summary of the Company's Investor Day, held today, Tuesday, January 20, 2026, at 11:00 a.m. Eastern time in New York City. The Investor Day was conducted both in-person and via webcast.A replay of the event can be found on the Investors section of the Company's website at https://investors.aytubio.com under Events & Presentations. The event can also be accessed directly at https://app.webinar.net/Qo7DrDvVzq8.The
- NEWSAytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUAEXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu RxConnect® pharmacies to support patient accessDENVER, COLORADO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines to treat complex central nervous system disorders and improve the quality of life of patients, today announced the nationwide commercial launch of EXXUA and successful completion of its launch meeting last week that finalized sales training and launch preparations for EXXUA, the first and only selec
AYTU FAQ
6 questionsWhat does Aytu BioPharma Inc. do?
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal...Where does AYTU stock trade?
Aytu BioPharma Inc. (AYTU) is listed on NASDAQ.What sector and industry is AYTU in?
Aytu BioPharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AYTU?
Aytu BioPharma Inc. has had 2 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $800.00 price target on 2025-07-01. Recent price targets range from $800.00 to $1200.00.What companies are similar to AYTU?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AYTU side-by-side with any of them on Quantisnow.How can I track AYTU on Quantisnow?
Quantisnow aggregates Aytu BioPharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AYTU to receive live email and push alerts on every new disclosure.